Arterial Capital Management is a private equity firm focused exclusively on the global life science sector. We specialise in providing equity funding to biotech, medtech and pharmaceutical companies.
Our investment approach is to fund well-researched, innovative projects, with proven management teams, recognised trial data, strong IP and a demonstrable opportunity for significant commercial upside. We target investee firms with an appetite for strong corporate governance, a desire to build a scalable business and the potential to return 5-20 times the gross investment within a three to six year timescale. Such opportunities are uncommon, but do exist.
At Arterial, our approach enables us to select the best investment opportunities available, attributable largely to the global reputation of our team, and their proven track record across the life science sector.
We place a strong emphasis upon ensuring our investments are attractive for Family Offices and Wealth Managers seeking qualifying investment opportunities for Tier 1 UK immigration visas, the UK Enterprise Investment Scheme (EIS) and international investments which comply with CRS / FATCA reporting requirements
In summary Arterial’s financial success is directly related to the financial return of all parties. We typically invest personally into each project on the same terms as other investors and we are motivated primarily by a traditional 20% carried interest on the successful realisation of a holding; thereby never losing sight of the fact that we all share a common goal – the conversion of outstanding science into commercial reality.
Arterial are unable to accept enquiries from members of the general public, but welcome enquiries from professional intermediaries.